| Name | Title | Contact Details |
|---|
Goodturn is a family of brands that provide automotive and tire repair and maintenance services. We partner with leading brands who are looking to accelerate their growth while offering greater opportunities for their employees to reach their fullest potential. Our company is built around delivering outstanding customer service and building winning cultures.
Our agency is the vision of a small group of insurance professionals who have spent years building large and mid-level risk management agencies. Mythic was born out of their desire to build an agency that caters to a select group of long-term clients who have an investment-minded view and value creativity and flexibility in a business partner. Although we have developed large specialty programs, such as our franchisor/franchisee risk management solution, we relish any opportunity to creatively craft custom risk management programs that mold to a clients specific needs. We offer expert guidance and flexibility to our clients, adjusting as their needs change and grow over time. Our ultimate goal is to make risk management and insurance profitable and as painless as possible.
IMUNON is a fully integrated, clinical stage biotechnology company focused on advancing a portfolio of innovative treatments that harness the bodys natural mechanisms to generate safe, effective, and durable responses across a broad array of human diseases. IMUNON has two platform technologies: Our TheraPlas® platform for the development of immunotherapies and other anti-cancer nucleic acid-based therapies and our PLACCINE platform for the development of nucleic acid vaccines for infectious diseases and cancer. The Companys lead clinical program, GEN-1, is a DNA-based immunotherapy for the localized treatment of advanced ovarian cancer currently in Phase II development. GEN-1 works by instructing the body to produce safe and durable levels of powerful cancer fighting molecules, such as interleukin-12 (IL-12) and interferon gamma (IFN-γ), at the tumor site. In addition, we are conducting pre-clinical proof-of-concept studies on a nucleic acid vaccine candidate targeting SARS-CoV-2 virus in order to validate our PLACCINE platform. IMUNONs platform technologies are based on the delivery of nucleic acids with novel synthetic delivery systems that are independent of viral vectors or devices. We will continue to leverage these platforms and to advance the technological frontier of plasmid DNA to better serve patients with difficult to treat conditions.